VIVORYON THERAPEUTICS NV (VVY.AS) Stock Price, Forecast & Analysis
Europe - AMS:VVY - NL00150002Q7 - Common Stock
VVY.AS Key Statistics, Chart & Performance
The current stock price of VVY.AS is 1.65 EUR. In the past month the price increased by 0.36%. In the past year, price decreased by -18.72%.
VVY.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.49 | 47.27B | ||
| 1AE.DE | ARGENX SE | 72.42 | 47.89B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.31B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.07B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.11B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.83B | ||
| 5CV.DE | CUREVAC NV | 5.3 | 1.04B | ||
| NANO.PA | NANOBIOTIX | N/A | 879.45M | ||
| PHIL.MI | PHILOGEN SPA | 20.7 | 690.06M | ||
| IVA.PA | INVENTIVA SA | N/A | 487.90M | ||
| FYB.DE | FORMYCON AG | N/A | 379.02M | ||
| VLA.PA | VALNEVA SE | N/A | 339.72M |
Related stock screener links
About VVY.AS
Company Profile
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
Company Info
VIVORYON THERAPEUTICS NV
Weinbergweg 22
HALLE SACHSEN-ANHALT DE
Employees: 14
Phone: 493455559900
VIVORYON THERAPEUTICS NV / VVY.AS FAQ
What does VIVORYON THERAPEUTICS NV do?
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. The company is headquartered in Halle, Sachsen-Anhalt and currently employs 14 full-time employees. The company went IPO on 2014-10-27. The firm has established a pipeline of orally available small molecule inhibitors for various indications, focused on oral small molecule-based therapeutics with a differentiated mode of action for treating diseases with inflammatory and/or fibrotic components, such as chronic diseases of the kidney or liver. The company focuses on chronic kidney disease (CKD), and more precisely- are initially targeting stage 3b and worse diabetic kidney disease (DKD). In addition to developing small molecule-based medicines, the Company is also pursuing antibody-based approaches for Alzheimer’s disease (AD).
What is the current price of VVY stock?
The current stock price of VVY.AS is 1.65 EUR. The price increased by 0.61% in the last trading session.
What is the dividend status of VIVORYON THERAPEUTICS NV?
VVY.AS does not pay a dividend.
What is the ChartMill technical and fundamental rating of VVY stock?
VVY.AS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is VVY.AS stock listed?
VVY.AS stock is listed on the Euronext Amsterdam exchange.
How is the market expecting VVY stock to perform?
7 analysts have analysed VVY.AS and the average price target is 5.23 EUR. This implies a price increase of 216.82% is expected in the next year compared to the current price of 1.65.
VVY.AS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VVY.AS. When comparing the yearly performance of all stocks, VVY.AS is a bad performer in the overall market: 75.46% of all stocks are doing better.
VVY.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS. While VVY.AS seems to be doing ok healthwise, there are quite some concerns on its profitability.
VVY.AS Financial Highlights
Over the last trailing twelve months VVY.AS reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.45% | ||
| ROE | -392.39% | ||
| Debt/Equity | 0 |
VVY.AS Forecast & Estimates
7 analysts have analysed VVY.AS and the average price target is 5.23 EUR. This implies a price increase of 216.82% is expected in the next year compared to the current price of 1.65.